<DOC>
	<DOCNO>NCT00693524</DOCNO>
	<brief_summary>Study evaluate benefit risk delay administration tacrolimus combine regimen mycophenolate mofetil monoclonal anti-IL2R antibody ( daclizumab ) , comparison standard steroid + tacrolimus double drug regimen</brief_summary>
	<brief_title>Sequential Therapy ( FK506 + Monoclonal Anti-IL2R Antibodies + MMF ) Versus FK506 With Steroids Liver TX</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Patient undergo orthotopic liver allograft transplantation . This include partial organ transplantation . Age donor 5 65 year Patient previously receive receive organ transplant ( include liver retransplantation ) Recipient auxiliary graft bioartificial liver use Patient receive living relate liver transplantation Patient require steroid well chemotherapy prior transplantation Patient previous history neoplastic disease type ( include leukaemia ) . However , patient primary liver carcinoma include meet follow criterion : &gt; 3 node No node large 5 cm No metastases No vascular invasion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>liver allograft transplantation</keyword>
	<keyword>sequential therapy</keyword>
	<keyword>tacrolimus</keyword>
</DOC>